107 related articles for article (PubMed ID: 10514343)
1. Physicochemistry, pharmacokinetics, and pharmacodynamics of S-nitrosocaptopril crystals, a new nitric oxide donor.
Jia L; Young X; Guo W
J Pharm Sci; 1999 Oct; 88(10):981-6. PubMed ID: 10514343
[TBL] [Abstract][Full Text] [Related]
2. Acute and subacute toxicity and efficacy of S-nitrosylated captopril, an ACE inhibitor possessing nitric oxide activities.
Jia L; Pei R; Lin M; Yang X
Food Chem Toxicol; 2001 Dec; 39(12):1135-43. PubMed ID: 11696388
[TBL] [Abstract][Full Text] [Related]
3. A novel S-nitrosocaptopril monohydrate for pulmonary arterial hypertension: H
Zhou Y; Lin M; Wang J; Chen F; Li F; Chen W; Han L; Wang C; Chen J; Shao JW; Jia L
Free Radic Biol Med; 2018 Dec; 129():107-115. PubMed ID: 30227269
[TBL] [Abstract][Full Text] [Related]
4. The effects of S-nitrosocaptopril on renal filtration and blood pressure in rats.
Jia L; Blantz RC
Eur J Pharmacol; 1998 Jul; 354(1):33-41. PubMed ID: 9726628
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo assessment of cellular permeability and pharmacodynamics of S-nitrosylated captopril, a nitric oxide donor.
Jia L; Wong H
Br J Pharmacol; 2001 Dec; 134(8):1697-704. PubMed ID: 11739246
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic effects of S-nitrosocaptopril crystals as a nitric oxide donor.
Jia L; Wu CC; Guo W; Young X
Eur J Pharmacol; 2000 Mar; 391(1-2):137-44. PubMed ID: 10720645
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of S-nitrosocaptopril on vasomotor tone.
Lin MJ; Yang XP; Wang J; Jia BJ; Jia L
Zhongguo Yao Li Xue Bao; 1998 Sep; 19(5):485-8. PubMed ID: 10375817
[TBL] [Abstract][Full Text] [Related]
8. [A design of a novel compound S-nitrosocaptopril possessing the capacities of both angiotensin converting enzyme inhibitors and NO donors].
Jia L
Sheng Li Ke Xue Jin Zhan; 1999 Jan; 30(1):53-6. PubMed ID: 12532851
[No Abstract] [Full Text] [Related]
9. S-Nitrosocaptopril prevents cancer metastasis in vivo by creating the hostile bloodstream microenvironment against circulating tumor cells.
Lu Y; Lian S; Ye Y; Yu T; Liang H; Cheng Y; Xie J; Zhu Y; Xie X; Yu S; Gao Y; Jia L
Pharmacol Res; 2019 Jan; 139():535-549. PubMed ID: 30366102
[TBL] [Abstract][Full Text] [Related]
10. Optimization of S-Nitrosocaptopril Monohydrate Storage Conditions Based on Response Surface Method.
Huang L; Zhou Y; Wang Y; Lin M
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946614
[TBL] [Abstract][Full Text] [Related]
11. A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: in vitro and in vivo characterization.
Zhao JH; Fu JH; Wang SM; Su CH; Shan Y; Kong SJ; Wang Y; Lu WL; Zhang H; Zhang S; Li L; Zhang EH; Wang L; Pei QL; Wang JC; Zhang X; Zhang Q
Int J Pharm; 2007 Jun; 337(1-2):88-101. PubMed ID: 17267147
[TBL] [Abstract][Full Text] [Related]
12. Relationship between angiotensin I blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive rats.
Sweet CS; Arbegast PT; Gaul SL; Blaine EH; Gross DM
Eur J Pharmacol; 1981 Dec; 76(2-3):167-76. PubMed ID: 6174351
[TBL] [Abstract][Full Text] [Related]
13. Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure.
Jackson EK; Dubinion JH; Mi Z
Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):29-34. PubMed ID: 18047624
[TBL] [Abstract][Full Text] [Related]
14. S-nitrosocaptopril interrupts adhesion of cancer cells to vascular endothelium by suppressing cell adhesion molecules via inhibition of the NF-кB and JAK/STAT signal pathways in endothelial cells.
Lian S; Lu Y; Cheng Y; Yu T; Xie X; Liang H; Ye Y; Jia L
Eur J Pharmacol; 2016 Nov; 791():62-71. PubMed ID: 27565222
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive activity of alacepril in spontaneously hypertensive rats and deoxycorticosterone acetate-salt hypertensive rats and dogs.
Takeyama K; Minato H; Fukuya F; Kawahara S; Hosoki K; Kadokawa T
Arzneimittelforschung; 1985; 35(10):1507-12. PubMed ID: 3000390
[TBL] [Abstract][Full Text] [Related]
16. Effect of nitric oxide on cytotoxicity of Taxol: enhanced Taxol transcellular permeability.
Jia L; Schweizer J; Wang Y; Cerna C; Wong H; Revilla M
Biochem Pharmacol; 2003 Dec; 66(11):2193-9. PubMed ID: 14609744
[TBL] [Abstract][Full Text] [Related]
17. ACE inhibition restores the vasodilator potency of the endothelium-derived relaxing factor, L-S-nitrosocysteine, in conscious Spontaneously Hypertensive rats.
Lewis SJ; Hashmi-Hill MP; Owen JR; Sandock K; Robertson TP; Bates JN
Vascul Pharmacol; 2006 Jun; 44(6):491-507. PubMed ID: 16713366
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive action of a novel orally active angiotensin converting enzyme inhibitor altiopril calcium (MC-838) in several hypertensive models of rats: comparison with captopril.
Aono J; Koga T; Yamazaki T; Shiraki Y; Sakai K
Arch Int Pharmacodyn Ther; 1988; 292():203-22. PubMed ID: 3293542
[TBL] [Abstract][Full Text] [Related]
19. Captopril and S-nitrosocaptopril as potent radiosensitizers: Comparative study and underlying mechanisms.
Jordan BF; Peeterbroeck J; Karroum O; Diepart C; Magat J; Grégoire V; Gallez B
Cancer Lett; 2010 Jul; 293(2):213-9. PubMed ID: 20144849
[TBL] [Abstract][Full Text] [Related]
20. Antihypertensive activity of alacepril, an orally active angiotensin converting enzyme inhibitor, in renal hypertensive rats and dogs.
Takeyama K; Minato H; Fukuya F; Kawahara S; Hosoki K; Kadokawa T
Arzneimittelforschung; 1985; 35(10):1502-7. PubMed ID: 3000389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
